Evidence map›Paper›PMID 38783317›Full record

ArticleMalaria journal2024

Evaluation of naturally acquired immune responses against novel pre-erythrocytic Plasmodium vivax proteins in a low endemic malaria population located in the Peruvian Amazon Basin.

Julio A Ventocilla, L Lorena Tapia, Reynaldo Ponce, Adriano Franco, Mindy Leelawong, Joao C Aguiar, G Christian Baldeviano, Brandon K Wilder

Abstract read
In one paragraph

Article in Malaria journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Julio A VentocillaVysnova Partners Inc., Bethesda, USA.
L Lorena TapiaU.S. Naval Medical Research Unit South, Lima-Peru (NAMRU SOUTH), Bellavista, Peru.
Reynaldo PonceInstituto Nacional de Salud (INS), Lima, Peru.
Adriano FrancoJohns Hopkins University, Baltimore, USA.
Mindy LeelawongU.S. Naval Medical Research Unit South, Lima-Peru (NAMRU SOUTH), Bellavista, Peru.
Joao C AguiarCAMRIS International, LLC, Bethesda, USA.
G Christian BaldevianoU.S. Naval Medical Research Unit South, Lima-Peru (NAMRU SOUTH), Bellavista, Peru.
Brandon K WilderU.S. Naval Medical Research Unit South, Lima-Peru (NAMRU SOUTH), Bellavista, Peru. wilderb@ohsu.edu.

Funding

Peru Infectious Diseases Epidemiology Research Training ConsortiumD43TW007393 · FIC · UNIVERSIDAD PERUANA CAYETANO HEREDIA · PI Andres G Lescano · 2005 to 2026
$5.9M
FIC NIH HHS D43 TW007393
6 · The paper itself

Abstract

backgroundPlasmodium vivax represents the most geographically widespread human malaria parasite affecting civilian and military populations in endemic areas. Targeting the pre-erythrocytic (PE) stage of the parasite life cycle is especially appealing for developing P. vivax vaccines as it would prevent disease and transmission. Here, naturally acquired immunity to a panel of P. vivax PE antigens was explored, which may facilitate vaccine development and lead to a better understanding of naturally acquired PE immunity.

methodsTwelve P. vivax PE antigens orthologous to a panel of P. falciparum antigens previously identified as highly immunogenic in protected subjects after immunization with radiation attenuated sporozoites (RAS) were used for evaluation of humoral and cellular immunity by ELISA and IFN-γ ELISpot. Samples from P. vivax infected individuals (n = 76) from a low endemic malaria region in the Peruvian Amazon Basin were used.

resultsIn those clinical samples, all PE antigens evaluated showed positive IgG antibody reactivity with a variable prevalence of 58-99% in recently P. vivax diagnosed patients. The magnitude of the IgG antibody response against PE antigens was lower compared with blood stage antigens MSP1 and DBP-II, although antibody levels persisted better for PE antigens (average decrease of 6% for PE antigens and 43% for MSP1, p < 0.05). Higher IgG antibodies was associated with one or more previous malaria episodes only for blood stage antigens (p < 0.001). High IgG responders across PE and blood stage antigens showed significantly lower parasitaemia compared to low IgG responders (median 1,921 vs 4,663 par/µl, p < 0.05). In a subgroup of volunteers (n = 17),positive IFN-γ T cell response by ELISPOT was observed in 35% vs 9-35% against blood stage MSP1 and PE antigens, respectively, but no correlation with IgG responses.

conclusionsThese results demonstrate clear humoral and T cell responses against P. vivax PE antigens in individuals naturally infected with P. vivax. These data identify novel attractive PE antigens suitable for use in the potential development and selection of new malaria vaccine candidates which can be used as a part of malaria prevention strategies in civilian and military populations living in P. vivax endemic areas.

Indexed as

Antigens, ProtozoanMalaria, VivaxPlasmodium vivaxProtozoan ProteinsAdolescentAdultAgedAntibodies, ProtozoanChildEnzyme-Linked Immunosorbent AssayEnzyme-Linked Immunospot AssayFemaleHumansImmunoglobulin GMaleMiddle AgedAntibodies, ProtozoanAntigens, ProtozoanImmunoglobulin GProtozoan ProteinsNatural acquired immunityPeruvian amazon BasinPlasmodium vivaxPre-erythrocytic stage

Identifiers

PMID38783317
PMCPMC11118720

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.